• Mohamad Mohty, Florent Malard, Bilal Mohty, Bipin Savani, Philippe Moreau, and Evangelos Terpos.
• Hematology Department, Saint-Antoine Hospital, Paris, France; INSERM (National Institute of Health and Medical Research) 938, Paris, France; Pierre and Marie Curie University, Paris, France.
• Cancer. 2014 Mar 1; 120 (5): 618-23.

AbstractBortezomib has demonstrated substantial activity in the treatment of patients with multiple myeloma and is widely incorporated into treatment strategies across the different settings. It is interesting to note that data are accumulating to suggest that the activity of bortezomib extends beyond the tumor cell and microenvironment to encompass effects on bone metabolism. Indeed, data from both the preclinical and clinical settings have suggested that bortezomib directly stimulates osteoblast growth and differentiation, while also inhibiting osteoclast development and activity. Notably, in the clinical setting, the bone anabolic effects of bortezomib could be demonstrated by the healing of lytic lesions as noted in some patients. These results are of importance because bone disease is a hallmark of myeloma and therefore any agent that combines antimyeloma activity with positive effects on bone is of substantial interest. However, further studies are needed to establish how the agent should be used for the treatment of patients with bone disease.© 2013 American Cancer Society.

46 keywords...

hide…